Search results for "CHIME"

showing 10 items of 124 documents

Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma

2021

Abstract Tisagenlecleucel (tisa‐cel) is a second‐generation autologous CD19‐targeted chimeric antigen receptor (CAR) T‐cell therapy approved for relapsed/refractory (R/R) large B‐cell lymphoma (LBCL). The approval was based on the results of phase II JULIET trial, with a best overall response rate (ORR) and complete response (CR) rate in infused patients of 52% and 40%, respectively. We report outcomes with tisa‐cel in the standard‐of‐care (SOC) setting for R/R LBCL. Data from all patients with R/R LBCL who underwent leukapheresis from December 2018 until June 2020 with the intent to receive SOC tisa‐cel were retrospectively collected at 10 Spanish institutions. Toxicities were graded accor…

Male0301 basic medicine:aminoácidos péptidos y proteínas::proteínas::proteínas de membranas::receptores de superficie celular::receptores inmunológicos::receptores de antígenos::receptores de antígenos de linfocitos T [COMPUESTOS QUÍMICOS Y DROGAS]Cancer Researchnon‐Hodgkin's lymphomaBest Overall Responsehematological cancer:Other subheadings::Other subheadings::/drug therapy [Other subheadings]Non- Hodgkin's lymphomaGastroenterology0302 clinical medicineMedicine research:Other subheadings::/therapeutic use [Other subheadings]CàncerB-cell lymphomaRC254-282CancerOriginal ResearchReceptors Chimeric AntigenNeoplasms. Tumors. Oncology. Including cancer and carcinogensnon&#8208Standard of CareMiddle AgedPatologiaHodgkin&aposProgression-Free SurvivalCytokine release syndromeclinical cancer researchOncology:neoplasias::neoplasias por tipo histológico::linfoma::linfoma no Hodgkin::linfoma de células B::linfoma de células B grandes difuso [ENFERMEDADES]030220 oncology & carcinogenesisCytokinesFemaleLymphoma Large B-Cell Diffusenon-Hodgkin's lymphomamedicine.medical_specialtyReceptors Antigen T-CellCèl·lules B - Tumors - Tractament:Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores]Investigació mèdicaReal world evidence03 medical and health sciencess lymphoma:Neoplasms::Neoplasms by Histologic Type::Lymphoma::Lymphoma Non-Hodgkin::Lymphoma B-Cell::Lymphoma Large B-Cell Diffuse [DISEASES]Refractoryclinical observationsInternal medicinemedicineHumansRadiology Nuclear Medicine and imagingLeukapheresis:Amino Acids Peptides and Proteins::Proteins::Membrane Proteins::Receptors Cell Surface::Receptors Immunologic::Receptors Antigen::Receptors Antigen T-Cell [CHEMICALS AND DRUGS]AgedRetrospective Studies:Otros calificadores::/uso terapéutico [Otros calificadores]business.industryTeràpia cel·lularClinical Cancer ResearchLeukapheresismedicine.diseaseMalaltia de HodgkinNon-Hodgkin's lymphomaLymphoma030104 developmental biologyHodgkin's diseaseNeoplasm Recurrence LocalbusinessCancer Medicine
researchProduct

Cytogenetic and molecular findings related to rhabdomyosarcoma. An analysis of seven cases.

2003

Rhabdomyosarcoma (RMS) is the most common soft-tissue sarcoma in childhood. Histologically, it is subdivided histologically into two main subtypes: alveolar (ARMS) and embryonal (ERMS). ARMS is characterized by t(2;13)(q35;q14) or its variant t(1;13)(p36;q14), which fuse PAX3 and PAX7, respectively, with FKHR to produce chimeric genes. ERMS is frequently associated with loss of heterozygosity of 11p15.5. We investigated seven RMS (three ARMS and four ERMS) by means of cytogenetic, fluorescence in situ hybridization, and molecular analyses, including the study of the main genes implicated in the G1- to S-phase cell cycle transition, and correlated these studies with pathologic findings and c…

MaleCancer ResearchPAX3Genes mycLocus (genetics)Chimeric geneBiologyLoss of heterozygosityGene duplicationRhabdomyosarcomaGeneticsmedicineHumansPaired Box Transcription FactorsRhabdomyosarcomaChildMolecular BiologyPAX3 Transcription FactorIn Situ Hybridization FluorescenceChromosome AberrationsHomeodomain Proteinsmedicine.diagnostic_testForkhead Box Protein O1Hybridization probePAX7 Transcription FactorForkhead Transcription Factorsmedicine.diseaseMolecular biologyDNA-Binding ProteinsChild PreschoolFemaleFluorescence in situ hybridizationTranscription FactorsCancer genetics and cytogenetics
researchProduct

Bone morphogenetic protein-4 is required for mesoderm formation and patterning in the mouse.

1995

Bone morphogenetic protein-4 (BMP-4) is a member of the TGF-beta superfamily of polypeptide signaling molecules, closely related to BMP-2 and to Drosophila decapentaplegic (DPP). To elucidate the role of BMP-4 in mouse development the gene has been inactivated by homologous recombination in ES cells. Homozygous mutant Bmp-4tm1blh embryos die between 6.5 and 9.5 days p.c., with a variable phenotype. Most Bmp-4tm1blh embryos do not proceed beyond the egg cylinder stage, do not express the mesodermal marker T(Brachyury), and show little or no mesodermal differentiation. Some homozygous mutants develop to the head fold or beating heart/early somite stage or beyond. However, they are development…

MaleMesodermBrachyuryHeterozygoteanimal structuresMolecular Sequence DataBiologyCell LineMesodermEmbryonic and Fetal DevelopmentMiceGeneticsmedicineParaxial mesodermAnimalsCrosses GeneticDecapentaplegicBase SequenceChimeraStem CellsHomozygoteProteinsGastrulaCell biologyMice Inbred C57BLmedicine.anatomical_structureBone morphogenetic protein 5PhenotypeBone morphogenetic protein 4GDF6embryonic structuresMesoderm formationBone Morphogenetic ProteinsGene TargetingFemaleDevelopmental BiologyGenesdevelopment
researchProduct

The Major Conformational IgE-binding Epitopes of Hevein (Hev b6.02) Are Identified by a Novel Chimera-based Allergen Epitope Mapping Strategy

2002

A novel approach to localize and reconstruct conformational IgE-binding epitope regions of hevein (Hev b6.02), a major natural rubber latex allergen, is described. An antimicrobial protein (AMP) from the amaranth Amaranthus caudatus was used as an immunologically non-IgE-binding adaptor molecule to which terminal or central parts of hevein were fused. Hevein and AMP share a structurally identical core region but have different N-terminal and C-terminal regions. Only 1 of 16 hevein-allergic patients showed weak IgE binding to purified native or recombinant AMP. Chimeric AMP with the hevein N terminus was recognized by IgE from 14 (88%) patients, and chimeric AMP with the hevein C terminus wa…

MaleModels MolecularProtein ConformationImmunoglobulin Emedicine.disease_causeBiochemistryEpitopelaw.inventionEpitopes0302 clinical medicineAllergenlawLectinsPlant Proteins0303 health sciencesbiologyMiddle Aged3. Good healthDatabases as TopicBiochemistryRecombinant DNAFemalePlant LectinsProtein BindingAdultPeptide BiosynthesisAdolescentRecombinant Fusion ProteinsEnzyme-Linked Immunosorbent Assay03 medical and health sciencesChimera (genetics)medicineAnimalsHumansMolecular BiologyAged030304 developmental biologyDose-Response Relationship DrugC-terminusCell BiologyAllergensImmunoglobulin EMolecular biologyAdenosine MonophosphateProtein Structure TertiaryN-terminusEpitope mappingSpectrometry Mass Matrix-Assisted Laser Desorption-Ionizationbiology.proteinChickensEpitope MappingAntimicrobial Cationic Peptides030215 immunologyJournal of Biological Chemistry
researchProduct

Morphological and genomic characterisation of the Schistosoma hybrid infecting humans in Europe reveals admixture between Schistosoma haematobium and…

2021

Schistosomes cause schistosomiasis, the world’s second most important parasitic disease after malaria in terms of public health and social-economic impacts. A peculiar feature of these dioecious parasites is their ability to produce viable and fertile hybrid offspring. Originally only present in the tropics, schistosomiasis is now also endemic in southern Europe. Based on the analysis of two genetic markers the European schistosomes had previously been identified as hybrids between the livestock- and the human-infective species Schistosoma bovis and Schistosoma haematobium, respectively. Here, using PacBio long-read sequencing technology we performed genome assembly improvement and annotati…

MalePhysiologyIntrogressionEggsRC955-962SnailsDisease Vectors0302 clinical medicineMedical ConditionsReproductive PhysiologyArctic medicine. Tropical medicineInvertebrate GenomicsMedicine and Health SciencesBody SizeSchistosomiasis0303 health sciences[SDV.BID.EVO]Life Sciences [q-bio]/Biodiversity/Populations and Evolution [q-bio.PE]EukaryotaGenomics3. Good healthEuropeInfectious DiseasesSchistosoma bovisSchistosoma haematobiumSchistosomaFemalePublic aspects of medicineRA1-1270SchistosomesResearch ArticleEvolutionary ProcessesBulinus030231 tropical medicine03 medical and health sciencesHelminthsParasitic diseaseparasitic diseasesGeneticsParasitic DiseasesAnimalsHumans[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology030304 developmental biologyEvolutionary BiologyGenome Helminth[SDV.GEN]Life Sciences [q-bio]/GeneticsChimeraPublic Health Environmental and Occupational HealthOrganismsBiology and Life SciencesPaleontologyInvertebratesAnimal GenomicsEarth SciencesHybridization GeneticPaleogeneticsZoology
researchProduct

Identification of optimal device combinations for the chimney endovascular aneurysm repair technique within the PERICLES registry

2018

Abstract Objective The ideal stent combination for chimney endovascular aneurysm repair remains undetermined. Therefore, we sought to identify optimal aortic and chimney stent combinations that are associated with the best outcomes by analyzing the worldwide collected experience in the PERformance of chImney technique for the treatment of Complex aortic pathoLogiES (PERICLES) registry. Methods The PERICLES registry was reviewed for patients with pararenal aortic disease electively treated from 2008 to 2014. Eleven different aortic devices were identified with three distinct subgroups: group A (n = 224), nitinol/polyester; group B (n = 105), stainless steel/polyester; and group C (n = 69), n…

MaleRegistrieTime FactorsEndoleakmedicine.medical_treatmentComorbidity030204 cardiovascular system & hematology030230 surgeryEndovascular aneurysm repairSettore MED/22 - Chirurgia VascolareAortic aneurysm0302 clinical medicineRisk FactorsRetrospective StudieOcclusionOdds RatioStentRegistriesMultivariate AnalysiPolytetrafluoroethyleneAged 80 and overEndovascular ProceduresHazard ratioGraft Occlusion VascularEuropeBlood Vessel ProsthesiTreatment OutcomeCardiothoracic surgeryStentsFemaleCardiology and Cardiovascular MedicineSTENT GRAFT; CHIMENY GRAFT; CHIMNEY TECHINQUEHumanUnited Statemedicine.medical_specialtyHospitals Low-VolumeTime FactorPolyestersPolyesterProsthesis DesignDisease-Free Survival03 medical and health sciencesBlood Vessel Prosthesis ImplantationBlood vessel prosthesisAlloysmedicineHumansProportional Hazards ModelsRetrospective StudiesAgedEndovascular ProcedureAortic Aneurysm Thoracicbusiness.industryRisk FactorStentOdds ratiomedicine.diseaseStainless SteelUnited StatesBlood Vessel ProsthesisSurgeryMultivariate AnalysisAlloyProportional Hazards ModelSurgerybusinessHospitals High-VolumeAortic Aneurysm Abdominal
researchProduct

Modulation of hippocampal theta oscillations and spatial memory by relaxin-3 neurons of the nucleus incertus.

2009

Hippocampal theta rhythm is thought to underlie learning and memory, and it is well established that “pacemaker” neurons in medial septum (MS) modulate theta activity. Recent studies in the rat demonstrated that brainstem-generated theta rhythm occurs through a multisynaptic pathway via the nucleus incertus (NI), which is the primary source of the neuropeptide relaxin-3 (RLN3). Therefore, this study examined the possible contribution of RLN3 to MS activity, and associated hippocampal theta activity and spatial memory. In anesthetized and conscious rats, we identified the ability of intraseptal RLN3 signaling to modulate neuronal activity in the MS and hippocampus and promote hippocampal the…

MaleStilbamidinesCognitive NeuroscienceMutant Chimeric ProteinsPresynaptic TerminalsHippocampusNeuropeptideBiotinNerve Tissue ProteinsHippocampal formationNeuropsychological TestsHippocampusRats Sprague-DawleyCellular and Molecular NeuroscienceMicroscopy Electron TransmissionMemoryPonsNeural PathwaysPremovement neuronal activityAnimalsInsulinTheta RhythmNeuronsAnalysis of VarianceBehavior AnimalRhodaminesSpectrum AnalysisRelaxinProteinsDextransSpontaneous alternationNucleus IncertusRatsNeuropsychology and Physiological Psychologynervous systemSpace PerceptionExploratory BehaviorCholinergicSeptum of BrainRelaxin-3PsychologyPeptidesNeuroscienceProto-Oncogene Proteins c-fosLearningmemory (Cold Spring Harbor, N.Y.)
researchProduct

A non-redundant role for OX40 in the competitive fitness of Treg in response to IL-2.

2010

OX40 stimulation is known to enhance activation of effector T cells and to inhibit induction and suppressive function of Treg. Here we uncovered a novel role of OX40 in sustaining Treg competitive fitness in vivo, during repopulation of lymphopenic hosts and reconstitution of BM chimeras. Defective expansion of OX40-null Treg diminished their ability to suppress inflammation in a model of lymphopenia-driven colitis. OX40-mediated promotion of Treg fitness spanned beyond lymphopenic environments, as endogenous Treg in OX40-null mice showed decreased accumulation during thymic development, enhanced susceptibility to antibody-mediated depletion and defective turnover following thymectomy. In v…

Malemedicine.medical_treatmentImmunologyBlotting Westernchemical and pharmacologic phenomenaEndogenyInflammationSuppressor of Cytokine Signaling ProteinsT-Lymphocytes RegulatoryMiceSuppressor of Cytokine Signaling 1 ProteinLymphopeniaOX40; Treg; IL-2.medicineSTAT5 Transcription FactorImmunology and AllergyAnimalsOX40PhosphorylationReceptorSTAT5Cell ProliferationMice KnockoutbiologyEffectorCell growthSuppressor of cytokine signaling 1hemic and immune systemsReceptors OX40IL-2.ColitisFlow Cytometrycytokinescompetitive fitnessSpecific Pathogen-Free OrganismsThymectomyMice Inbred C57BLTregRadiation ChimeraImmunologybiology.proteinInterleukin-2costimulatory moleculesmedicine.symptomcompetitive fitness; costimulatory molecules; cytokines; treg
researchProduct

Équidistribution non archimédienne et actions de groupes sur les arbres = Non-Archimedean equidistribution and group actions on trees

2016

We give equidistribution results of elements of function fields over finite fields, and of quadratic irrationals over these fields, in their completed local fields. We deduce these results from equidistribution theorems of common perpendiculars in quotients of trees by lattices in their automorphism groups, proved by using ergodic properties of the discrete geodesic flow. Nous donnons des résultats d'équidistribution d'éléments de corps de fonctions sur des corps finis, et d'irrationnels quadratiques sur ces corps, dans leurs corps locaux complétés. Nous déduisons ces résultats de théorèmes d'équidistribution de perpendiculaires communes dans des quotients d'arbres par des réseaux de leur g…

Mathematics::History and Overviewnon-archimedean equidistribution
researchProduct

Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE)

2021

Abstract Background Effective treatments are still needed to reduce the severity of symptoms, time of hospitalization, and mortality of COVID-19. SARS-CoV-2 specific memory T-lymphocytes obtained from convalescent donors recovered can be used as passive cell immunotherapy. Methods Between September and November 2020 a phase 1, dose-escalation, single centre clinical trial was conducted to evaluate the safety and feasibility of the infusion of CD45RA− memory T cells containing SARS-CoV-2 specific T cells as adoptive cell therapy against moderate/severe cases of COVID-19. Nine participants with pneumonia and/or lymphopenia and with at least one human leukocyte antigen (HLA) match with the don…

Medicine (General)medicine.medical_specialtybusiness.industrymedicine.medical_treatmentLymphocyteMicrochimerismGeneral MedicineImmunotherapyEarly warning scoreCell therapyClinical trialR5-920Clinical researchmedicine.anatomical_structureInternal medicinemedicinebusinessAdverse effectResearch PaperEClinicalMedicine
researchProduct